Amneal supports Congress' efforts to ensure essential medicines are Made in AmericaBusiness Wire • 08/22/22
Amneal Pharmaceuticals, Inc. (AMRX) Management Team on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and IntegrationBusiness Wire • 06/07/22
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord DisordersBusiness Wire • 06/01/22
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)Business Wire • 05/27/22
Amneal Pharmaceuticals, Inc. (AMRX) Management Team on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/04/22
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)Business Wire • 04/13/22
Amneal Pharmaceuticals: Generics And Biosimilars Play Has Strong Upside Potential Under New / Old ManagementSeeking Alpha • 03/30/22
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual MeetingBusiness Wire • 03/24/22
Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income CountriesBusiness Wire • 03/17/22
Amneal Pharmaceuticals (AMRX) CEO, Chirag Patel on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/02/22
Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)Business Wire • 03/01/22
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 02/23/22